GSM5359442
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.430
- KRAS_SIGNALING_DN+0.400
- SPERMATOGENESIS+0.290
- MYOGENESIS+0.170
- CHOLESTEROL_HOMEOSTASIS+0.160
- HEDGEHOG_SIGNALING+0.160
- APICAL_SURFACE+0.150
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.140
- HYPOXIA+0.120
- NOTCH_SIGNALING+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- MYC_TARGETS_V2-0.480
- OXIDATIVE_PHOSPHORYLATION-0.450
- MYC_TARGETS_V1-0.420
- INTERFERON_GAMMA_RESPONSE-0.400
- PI3K_AKT_MTOR_SIGNALING-0.400
- DNA_REPAIR-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.360
- FATTY_ACID_METABOLISM-0.330
- MITOTIC_SPINDLE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013484 | — | cohortA4 | 0.895 |
| 2 | SRR1361674 | GTEX | — | 0.866 |
| 3 | MNG835 | — | — | 0.862 |
| 4 | SRR1516039 | — | — | 0.861 |
| 5 | SRR26320080 | — | — | 0.856 |
| 6 | SRR1352975 | GTEX | — | 0.856 |
| 7 | BS_KPT2WPHW | Ganglioglioma | — | 0.854 |
| 8 | SRR12202469 | — | — | 0.854 |
| 9 | 82982 | EPN | Supratentorial EPN | 0.853 |
| 10 | SRR4296064 | — | cohortA1 | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| COAGULATION | 0.060 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |